ClinicaliQ Trial Snapshot
- Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07610395.
- Treatment Being Tested: Two different oral doses of vapendavir (an investigational antiviral) versus placebo in COPD patients with rhinovirus (RV) infection, aimed at reducing respiratory symptom severity and duration.
- Patient Eligibility Overview: Adults with COPD who have confirmed or suspected rhinovirus respiratory tract infection; trial excludes those with severe exacerbations requiring hospitalization or mechanical ventilation.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and/or duration of respiratory symptoms associated with RV infections in patients with COPD.
Eligibility Snapshot
- Inclusion Sign informed consent for study participation and medical records release (if needed). Male or female age ≥40 years and ≤85 years at the time of signing the informed consent at Screening. If sexually active and/or of child-bearing potential (both females and males), must agree to use a highly effective form of contraception at the time of randomization until 30 days (females) or 90 days (males) after the last dose. Female participants may not use hormonal birth control as a sole method. Participants will be asked to commit to this criterion at screening even though it does not need to be implemented until treatment is received. See Section 11.2 below. Confirmed diagnosis of COPD, defined as chronic cough, sputum production, and/or dyspnea with airflow obstruction which is not fully reversible (that is, post bronchodilator FEV1/FVC ratio
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.